• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Maintenance Poly (ADP-ribose) Polymerase Inhibitor Therapy for Ovarian Cancer: Precision Oncology or One Size Fits All?

作者信息

Berchuck Andrew, Secord Angeles Alvarez, Moss Haley A, Havrilesky Laura J

机构信息

Andrew Berchuck, Angeles Alvarez Secord, Haley A. Moss, and Laura J. Havrilesky, Duke University Medical Center, Durham, NC.

出版信息

J Clin Oncol. 2017 Dec 20;35(36):3999-4002. doi: 10.1200/JCO.2017.74.5752. Epub 2017 Oct 26.

DOI:10.1200/JCO.2017.74.5752
PMID:29072978
Abstract
摘要

相似文献

1
Maintenance Poly (ADP-ribose) Polymerase Inhibitor Therapy for Ovarian Cancer: Precision Oncology or One Size Fits All?卵巢癌的维持性聚（ADP-核糖）聚合酶抑制剂治疗：精准肿瘤学还是一刀切？
J Clin Oncol. 2017 Dec 20;35(36):3999-4002. doi: 10.1200/JCO.2017.74.5752. Epub 2017 Oct 26.
2
U.S. Food and Drug Administration-Approved Poly (ADP-Ribose) Polymerase Inhibitor Maintenance Therapy for Recurrent Ovarian Cancer: A Cost-Effectiveness Analysis.美国食品和药物管理局批准的聚（ADP-核糖）聚合酶抑制剂维持治疗复发性卵巢癌：成本效益分析。
Obstet Gynecol. 2019 Apr;133(4):795-802. doi: 10.1097/AOG.0000000000003171.
3
Selecting new upfront regimens for advanced ovarian cancer with biomarker guidance.在生物标志物指导下为晚期卵巢癌选择新的一线治疗方案。
Gynecol Oncol. 2020 Dec;159(3):604-606. doi: 10.1016/j.ygyno.2020.09.017. Epub 2020 Sep 28.
4
PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis.PARP 抑制剂维持治疗铂敏感复发性卵巢癌患者的成本效果分析。
Gynecol Oncol. 2015 Oct;139(1):59-62. doi: 10.1016/j.ygyno.2015.08.013. Epub 2015 Aug 22.
5
[Poly (ADP-Ribose) Polymerase Inhibitors--Current Status and Future Developments].[聚（ADP - 核糖）聚合酶抑制剂——现状与未来发展]
Gan To Kagaku Ryoho. 2016 Feb;43(2):193-7.
6
Efficacy and safety updates of poly ADP-ribose polymerase (PARP) inhibitor maintenance in ovarian cancer from ASCO 2020.2020年美国临床肿瘤学会（ASCO）关于聚腺苷酸二磷酸核糖聚合酶（PARP）抑制剂维持治疗卵巢癌的疗效与安全性更新
Int J Gynecol Cancer. 2020 Aug;30(8):1256-1257. doi: 10.1136/ijgc-2020-001723. Epub 2020 Jul 9.
7
[PARP inhibitors in first-line of ovarian cancers].[聚（ADP-核糖）聚合酶抑制剂用于卵巢癌一线治疗]
Bull Cancer. 2020 Jan;107(1):4-5. doi: 10.1016/j.bulcan.2019.10.009. Epub 2020 Jan 10.
8
Cost-effectiveness analysis comparing "PARP inhibitors-for-all" to the biomarker-directed use of PARP inhibitor maintenance therapy for newly diagnosed advanced stage ovarian cancer.比较“PARP 抑制剂广泛应用”与基于生物标志物的 PARP 抑制剂维持治疗用于新诊断的晚期卵巢癌的成本效益分析。
Gynecol Oncol. 2020 Nov;159(2):483-490. doi: 10.1016/j.ygyno.2020.08.003. Epub 2020 Aug 27.
9
Poly (ADP-ribose) polymerase inhibitors in the management of ovarian cancer.聚（ADP-核糖）聚合酶抑制剂在卵巢癌治疗中的应用
Womens Health (Lond). 2018 Jan-Dec;14:1745505717750694. doi: 10.1177/1745505717750694.
10
Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.聚（ADP - 核糖）聚合酶抑制剂在高级别浆液性卵巢癌中的临床应用
Oncologist. 2016 May;21(5):586-93. doi: 10.1634/theoncologist.2015-0438. Epub 2016 Mar 28.

引用本文的文献

1
Understanding the needs and perspectives of ovarian cancer patients when considering PARP inhibitor maintenance therapy: Findings from two online community events.在考虑PARP抑制剂维持治疗时了解卵巢癌患者的需求和观点：两项在线社区活动的结果
Gynecol Oncol Rep. 2022 Jul 26;43:101050. doi: 10.1016/j.gore.2022.101050. eCollection 2022 Oct.
2
Age of ovarian cancer diagnosis among BRIP1, RAD51C, and RAD51D mutation carriers identified through multi-gene panel testing.通过多基因panel 检测鉴定出 BRIP1、RAD51C 和 RAD51D 突变携带者的卵巢癌诊断年龄。
J Ovarian Res. 2021 Apr 29;14(1):61. doi: 10.1186/s13048-021-00809-w.
3
An aptamer interacting with heat shock protein 70 shows therapeutic effects and prognostic ability in serous ovarian cancer.
一种与热休克蛋白70相互作用的适体在浆液性卵巢癌中显示出治疗效果和预后评估能力。
Mol Ther Nucleic Acids. 2021 Jan 5;23:757-768. doi: 10.1016/j.omtn.2020.12.025. eCollection 2021 Mar 5.
4
Olaparib as maintenance treatment for patients with platinum-sensitive relapsed ovarian cancer.奥拉帕利作为铂敏感复发性卵巢癌患者的维持治疗药物。
Ther Adv Med Oncol. 2019 May 22;11:1758835919849753. doi: 10.1177/1758835919849753. eCollection 2019.
5
Targeted composite value-based endpoints in platinum-sensitive recurrent ovarian cancer.铂敏感复发性卵巢癌的靶向复合价值为基础的终点。
Gynecol Oncol. 2019 Mar;152(3):445-451. doi: 10.1016/j.ygyno.2018.11.028.
6
U.S. Food and Drug Administration-Approved Poly (ADP-Ribose) Polymerase Inhibitor Maintenance Therapy for Recurrent Ovarian Cancer: A Cost-Effectiveness Analysis.美国食品和药物管理局批准的聚（ADP-核糖）聚合酶抑制剂维持治疗复发性卵巢癌：成本效益分析。
Obstet Gynecol. 2019 Apr;133(4):795-802. doi: 10.1097/AOG.0000000000003171.